KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Accumulated Expenses: 2018-2025

Historic Accumulated Expenses for Twist Bioscience (TWST) over the last 7 years, with Sep 2025 value amounting to $31.3 million.

  • Twist Bioscience's Accumulated Expenses fell 7.02% to $31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.3 million, marking a year-over-year decrease of 7.02%. This contributed to the annual value of $31.3 million for FY2025, which is 7.02% down from last year.
  • Per Twist Bioscience's latest filing, its Accumulated Expenses stood at $31.3 million for Q3 2025, which was up 7.99% from $29.0 million recorded in Q2 2025.
  • In the past 5 years, Twist Bioscience's Accumulated Expenses ranged from a high of $33.6 million in Q3 2024 and a low of $14.9 million during Q1 2021.
  • In the last 3 years, Twist Bioscience's Accumulated Expenses had a median value of $25.8 million in 2023 and averaged $26.9 million.
  • In the last 5 years, Twist Bioscience's Accumulated Expenses spiked by 72.80% in 2021 and then dropped by 10.70% in 2023.
  • Over the past 5 years, Twist Bioscience's Accumulated Expenses (Quarterly) stood at $18.7 million in 2021, then grew by 24.24% to $23.3 million in 2022, then fell by 10.70% to $20.8 million in 2023, then climbed by 4.59% to $21.7 million in 2024, then decreased by 7.02% to $31.3 million in 2025.
  • Its Accumulated Expenses was $31.3 million in Q3 2025, compared to $29.0 million in Q2 2025 and $24.9 million in Q1 2025.